ArticleOncoTargets and therapy2021

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.

Qiansong Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.